<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39362028</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1090-2104</ISSN><JournalIssue CitedMedium="Internet"><Volume>734</Volume><PubDate><Year>2024</Year><Month>Nov</Month><Day>19</Day></PubDate></JournalIssue><Title>Biochemical and biophysical research communications</Title><ISOAbbreviation>Biochem Biophys Res Commun</ISOAbbreviation></Journal><ArticleTitle>Famotidine increases cellular phospho-tyrosine levels.</ArticleTitle><Pagination><StartPage>150763</StartPage><MedlinePgn>150763</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbrc.2024.150763</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0006-291X(24)01299-3</ELocationID><Abstract><AbstractText>While vaccines were being developed, the SARS-CoV-2 pandemic triggered a race to find known drugs that could be quickly repurposed to treat patients. One such candidate was famotidine, which retrospective cohort studies had shown increased survival in hospitalized patients. Computational studies had suggested that famotidine may target early viral proteases; however, ultimately, famotidine was shown not to function as a viral inhibitor. In contrast, we have observed a change in the cellular levels of phospho-tyrosine in A549 lung epithelial cells following treatment with famotidine. This quick change in phosphorylation was due mainly to a dose-dependent increase in cellular production of H<sub>2</sub>O<sub>2</sub>. Notably, these changes in phospho-tyrosine levels were able to affect cell signaling; we detected an increased short- and long-term response to IFNα stimulation. Our results suggest that famotidine can increase the anti-viral state of non-infected cells thereby potentially increasing viral resistance.</AbstractText><CopyrightInformation>Copyright © 2024 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zubiete-Franco</LastName><ForeName>Imanol</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 11724, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tonks</LastName><ForeName>Nicholas K</ForeName><Initials>NK</Initials><AffiliationInfo><Affiliation>Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 11724, USA. Electronic address: tonks@cshl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA045508</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA053840</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK124907</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 CA053840</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biochem Biophys Res Commun</MedlineTA><NlmUniqueID>0372516</NlmUniqueID><ISSNLinking>0006-291X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>5QZO15J2Z8</RegistryNumber><NameOfSubstance UI="D015738">Famotidine</NameOfSubstance></Chemical><Chemical><RegistryNumber>21820-51-9</RegistryNumber><NameOfSubstance UI="D019000">Phosphotyrosine</NameOfSubstance></Chemical><Chemical><RegistryNumber>BBX060AN9V</RegistryNumber><NameOfSubstance UI="D006861">Hydrogen Peroxide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>42HK56048U</RegistryNumber><NameOfSubstance UI="D014443">Tyrosine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015738" MajorTopicYN="Y">Famotidine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072283" MajorTopicYN="N">A549 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019000" MajorTopicYN="N">Phosphotyrosine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006861" MajorTopicYN="N">Hydrogen Peroxide</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014443" MajorTopicYN="N">Tyrosine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Covid-19</Keyword><Keyword MajorTopicYN="N">Famotidine</Keyword><Keyword MajorTopicYN="N">Histamine 2 receptor</Keyword><Keyword MajorTopicYN="N">Interferon alpha</Keyword><Keyword MajorTopicYN="N">Reactive oxygen species</Keyword><Keyword MajorTopicYN="N">Tyrosine phosphorylation</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Nicholas K. Tonks reports financial support was provided by National Institute of Health grants CA53840 and DK124907, the CSHL Cancer Centre Support Grant CA45508, the Robertson Research Fund of CSHL, the Don Monti Memorial Research Foundation, theHansen Foundation, and theSimons Foundation. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>19</Day><Hour>16</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>20</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>18</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39362028</ArticleId><ArticleId IdType="mid">NIHMS2027053</ArticleId><ArticleId IdType="pmc">PMC11490372</ArticleId><ArticleId IdType="doi">10.1016/j.bbrc.2024.150763</ArticleId><ArticleId IdType="pii">S0006-291X(24)01299-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Parvathaneni V, Gupta V, Utilizing drug repurposing against COVID-19 – Efficacy, limitations, and challenges, Life Sci. 259 (2020) 118275. 10.1016/j.lfs.2020.118275.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.118275</ArticleId><ArticleId IdType="pmc">PMC7430345</ArticleId><ArticleId IdType="pubmed">32818545</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato Y, Nishiyama K, Nishimura A, Noda T, Okabe K, Kusakabe T, Kanda Y, Nishida M, Drug repurposing for the treatment of COVID-19, J. Pharmacol. Sci 149 (2022) 108–114. 10.1016/j.jphs.2022.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jphs.2022.04.007</ArticleId><ArticleId IdType="pmc">PMC9040495</ArticleId><ArticleId IdType="pubmed">35641023</ArticleId></ArticleIdList></Reference><Reference><Citation>Panula P, Chazot PL, Cowart M, Gutzmer R, Leurs R, Liu WLS, Stark H, Thurmond RL, Haas HL, International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors, Pharmacol. Rev 67 (2015) 601–655. 10.1124/pr.114.010249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/pr.114.010249</ArticleId><ArticleId IdType="pmc">PMC4485016</ArticleId><ArticleId IdType="pubmed">26084539</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldi M, Borriello F, Granata F, Annunziato L, Marone G, Histamine Receptors and Antihistamines: From Discovery to Clinical Applications, (2014). 10.1159/000358740.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000358740</ArticleId><ArticleId IdType="pubmed">24925401</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace AW, Cirillo PM, Ryan JC, Krigbaum NY, Badathala A, Cohn BA, Association of the patterns of use of medications with mortality of COVID-19 infection: a hospital-based observational study, BMJ Open 11 (2021) e050051. 10.1136/bmjopen-2021-050051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2021-050051</ArticleId><ArticleId IdType="pmc">PMC8720638</ArticleId><ArticleId IdType="pubmed">34972763</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, Wang Q, Xu Y, Li M, Li X, Zheng M, Chen L, Li H, Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods, Acta Pharm. Sin. B 10 (2020) 766–788. 10.1016/j.apsb.2020.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2020.02.008</ArticleId><ArticleId IdType="pmc">PMC7102550</ArticleId><ArticleId IdType="pubmed">32292689</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilianski A, Baker SC, Cell-based antiviral screening against coronaviruses: Developing virus-specific and broad-spectrum inhibitors, Antiviral Res. 101 (2014) 105–112. 10.1016/j.antiviral.2013.11.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2013.11.004</ArticleId><ArticleId IdType="pmc">PMC3931262</ArticleId><ArticleId IdType="pubmed">24269477</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamison DA, Anand Narayanan S, Trovão NS, Guarnieri JW, Topper MJ, Moraes-Vieira PM, Zaksas V, Singh KK, Wurtele ES, Beheshti A, A comprehensive SARS-CoV-2 and COVID-19 review, Part 1: Intracellular overdrive for SARS-CoV-2 infection, Eur. J. Hum. Genet 30 (2022) 889–898. 10.1038/s41431-022-01108-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41431-022-01108-8</ArticleId><ArticleId IdType="pmc">PMC9108708</ArticleId><ArticleId IdType="pubmed">35577935</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourinbaiar AS, Fruhstorfer EC, The effect of histamine type 2 receptor antagonists on human immunodeficiency virus (HIV) replication: Identification of a new class of antiviral agents, Life Sci. 59 (1996) PL365–PL370. 10.1016/s0024-3205(96)00553-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0024-3205(96)00553-x</ArticleId><ArticleId IdType="pubmed">8950301</ArticleId></ArticleIdList></Reference><Reference><Citation>Freedberg DE, Conigliaro J, Wang TC, Tracey KJ, Callahan MV, Abrams JA, Sobieszczyk ME, Markowitz DD, Gupta A, O’Donnell MR, Li J, Tuveson DA, Jin Z, Turner WC, Landry DW, Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study, Gastroenterology 159 (2020) 1129–1131.e3. 10.1053/j.gastro.2020.05.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.05.053</ArticleId><ArticleId IdType="pmc">PMC7242191</ArticleId><ArticleId IdType="pubmed">32446698</ArticleId></ArticleIdList></Reference><Reference><Citation>Janowitz T, Gablenz E, Pattinson D, Wang TC, Conigliaro J, Tracey K, Tuveson D, Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series, Gut 69(2020)1592–1597. 10.1136/gutjnl-2020-321852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-321852</ArticleId><ArticleId IdType="pmc">PMC7299656</ArticleId><ArticleId IdType="pubmed">32499303</ArticleId></ArticleIdList></Reference><Reference><Citation>Malone RW, Tisdall P, Fremont-Smith P, Liu Y, Huang X-P, White KM, Miorin L, Moreno E, Alon A, Delaforge E, Hennecker CD, Wang G, Pottel J, Blair RV, Roy CJ, Smith N, Hall JM, Tomera KM, Shapiro G, Mittermaier A, Kruse AC, García-Sastre A, Roth BL, Glasspool-Malone J, Ricke DO, COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms, Front.Pharmacol 12 (2021). https://www.frontiersin.org/articles/10.3389/fphar.2021.633680 (accessed December 6, 2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.633680</ArticleId><ArticleId IdType="pmc">PMC8021898</ArticleId><ArticleId IdType="pubmed">33833683</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee R, Bhattacharya A, Bojkova D, Mehdipour AR, Shin D, Khan KS, Hei-Yin Cheung H, Wong K-B, Ng W-L, Cinatl J, Geurink PP, van der Heden van Noort GJ, Rajalingam K, Ciesek S, Hummer G, Dikic I, Famotidine inhibits toll-like receptor 3-mediated inflammatory signaling in SARS-CoV-2 infection, J.Biol.Chem 297(2021)100925. 10.1016/j.jbc.2021.100925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2021.100925</ArticleId><ArticleId IdType="pmc">PMC8241579</ArticleId><ArticleId IdType="pubmed">34214498</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider WM, Chevillotte MD, Rice CM, Interferon-Stimulated Genes: A Complex Web of Host Defenses, Annu. Rev. Immunol 32(2014)513–545. 10.1146/annurev-immunol-032713-120231.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-032713-120231</ArticleId><ArticleId IdType="pmc">PMC4313732</ArticleId><ArticleId IdType="pubmed">24555472</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoggins JW, Interferon-Stimulated Genes: What Do They All Do?, Annu. Rev. Virol 6 (2019) 567–584. 10.1146/annurev-virology-092818-015756.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-virology-092818-015756</ArticleId><ArticleId IdType="pubmed">31283436</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiganis T., PTP1B and TCPTP – nonredundant phosphatases in insulin signaling and glucose homeostasis, FEBS J. 280 (2013) 445–458.10.1111/j.1742-4658.2012.08563.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-4658.2012.08563.x</ArticleId><ArticleId IdType="pubmed">22404968</ArticleId></ArticleIdList></Reference><Reference><Citation>Song D, Adrover JM, Felice C, Christensen LN, He X-Y, Merrill JR, Wilkinson JE, Janowitz T, Lyons SK, Egeblad M, Tonks NK, PTP1B inhibitors protect against acute lung injury and regulate CXCR4 signaling in neutrophils, JCI Insight 7(2022). 10.1172/jci.insight.158199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.158199</ArticleId><ArticleId IdType="pmc">PMC9431713</ArticleId><ArticleId IdType="pubmed">35866483</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes CP, Fernandes DE, Casimiro F, da Mata GF, Passos MT, Varela P, Mastroianni-Kirsztajn G, Pesquero JB, Cathepsin L in COVID-19: From Pharmacological Evidences to Genetics, Front. Cell. Infect. Microbiol 10 (2020). https://www.frontiersin.org/articles/10.3389/fcimb.2020.589505 (accessed October 24, 2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2020.589505</ArticleId><ArticleId IdType="pmc">PMC7753008</ArticleId><ArticleId IdType="pubmed">33364201</ArticleId></ArticleIdList></Reference><Reference><Citation>Echizen H, Ishizaki T, Clinical Pharmacokinetics of Famotidine, Clin. Pharmacokinet. 21 (1991)178–194.</Citation><ArticleIdList><ArticleId IdType="pubmed">1764869</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemmon MA, Freed DM, Schlessinger J, Kiyatkin A, The Dark Side of Cell Signaling: Positive Roles for Negative Regulators, Cell 164 (2016) 1172–1184. 10.1016/j.cell.2016.02.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.02.047</ArticleId><ArticleId IdType="pmc">PMC4830124</ArticleId><ArticleId IdType="pubmed">26967284</ArticleId></ArticleIdList></Reference><Reference><Citation>Tonks NK, Redox Redux: Revisiting PTPs and the Control of Cell Signaling, Cell 121 (2005) 667–670. 10.1016/j.cell.2005.05.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2005.05.016</ArticleId><ArticleId IdType="pubmed">15935753</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng Y, High K, Antonello J, Washabaugh MW, Zhao Q, Enhanced sensitivity and precision in an enzyme-linked immunosorbent assay with fluorogenic substrates compared with commonly used chromogenic substrates, Anal. Biochem. 345 (2005) 227–236. 10.1016/j.ab.2005.07.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ab.2005.07.026</ArticleId><ArticleId IdType="pubmed">16137635</ArticleId></ArticleIdList></Reference><Reference><Citation>Wickenhagen A, Sugrue E, Lytras S, Kuchi S, Noerenberg M, Turnbull ML, Loney C, Herder V, Allan J, Jarmson I, Cameron-Ruiz N, Varjak M, Pinto RM, Lee JY, Iselin L, Palmalux N, Stewart DG, Swingler S, Greenwood EJD, Crozier TWM, Gu Q, Davies EL, Clohisey S, Wang B, Trindade Maranhão Costa F, Freire Santana M, de Lima Ferreira LC, Murphy L, Fawkes A, Meynert A, Grimes G, ISARIC4C Investigators, Da Silva Filho JL, Marti M, Hughes J, Stanton RJ, Wang ECY, Ho A, Davis I, Jarrett RF, Castello A, Robertson DL, Semple MG, Openshaw PJM, Palmarini M, Lehner PJ, Baillie JK, Rihn SJ, Wilson SJ, A prenylated dsRNA sensor protects against severe COVID-19, Science 374 (2021) eabj3624. 10.1126/science.abj3624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abj3624</ArticleId><ArticleId IdType="pmc">PMC7612834</ArticleId><ArticleId IdType="pubmed">34581622</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrau L, Frere JJ, Golynker I, Fajardo A, Rivera CF, Horiuchi S, Roonprapunt T, Minkoff JM, Blanco-Melo D, TenOever B, Delayed engagement of host defenses enables SARS-CoV-2 viremia and productive infection of distal organs in the hamster model of COVID-19, Sci. Signal. 16 (2023) eadg5470. 10.1126/scisignal.adg5470.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.adg5470</ArticleId><ArticleId IdType="pubmed">37311033</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Bogunovic D, Payelle-Brogard B, Francois-Newton V, Speer SD, Yuan C, Volpi S, Li Z, Sanal O, Mansouri D, Tezcan I, Rice GI, Chen C, Mansouri N, Mahdaviani SA, Itan Y, Boisson B, Okada S, Zeng L, Wang X, Jiang H, Liu W, Han T, Liu D, Ma T, Wang B, Liu M, Liu J-Y, Wang QK, Yalnizoglu D, Radoshevich L, Uzé G, Gros P, Rozenberg F, Zhang S-Y, Jouanguy E, Bustamante J, García-Sastre A, Abel L, Lebon P, Notarangelo LD, Crow YJ, Boisson-Dupuis S, Casanova J-L, Pellegrini S, Human intracellular ISG15 prevents interferon-α/β over-amplification and auto-inflammation, Nature 517 (2015) 89–93. 10.1038/nature13801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13801</ArticleId><ArticleId IdType="pmc">PMC4303590</ArticleId><ArticleId IdType="pubmed">25307056</ArticleId></ArticleIdList></Reference><Reference><Citation>Francois-Newton V, Livingstone M, Payelle-Brogard B, Uzé G, Pellegrini S, USP18 establishes the transcriptional and anti-proliferative interferon α/β differential, Biochem. J. 446 (2012) 509–516. 10.1042/BJ20120541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BJ20120541</ArticleId><ArticleId IdType="pubmed">22731491</ArticleId></ArticleIdList></Reference><Reference><Citation>Petry A, Görlach A, Regulation of NADPH Oxidases by G Protein-Coupled Receptors, Antioxid. Redox Signal. 30 (2019) 74–94. 10.1089/ars.2018.7525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2018.7525</ArticleId><ArticleId IdType="pubmed">29466865</ArticleId></ArticleIdList></Reference><Reference><Citation>De Deken X, Corvilain B, Dumont JE, Miot F, Roles of DUOX-Mediated Hydrogen Peroxide in Metabolism, Host Defense, and Signaling, Antioxid. Redox Signal. 20 (2014) 2776–2793. 10.1089/ars.2013.5602.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2013.5602</ArticleId><ArticleId IdType="pubmed">24161126</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer H, Mechanisms and Function of DUOX in Epithelia of the Lung, Antioxid. Redox Signal. 11 (2009) 2453–2465. 10.1089/ars.2009.2558.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2009.2558</ArticleId><ArticleId IdType="pmc">PMC2823369</ArticleId><ArticleId IdType="pubmed">19358684</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>